Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19124828 | 0.92 | HTR5A (0.37) | CNR1CNR2HSD17B14HTR5AMAP4K4 | |
| SCHEMBL17845139 | 0.88 | CNR1 (0.43) | CNR1CNR2RAB9APTGS2MAPT | |
| SCHEMBL17845114 | 0.79 | CNR1 (0.35) | CNR1CNR2RAB9AALDH1A1MAPT | |
| SCHEMBL17845135 | 0.79 | RAB9A (0.44) | RAB9AALDH1A1MAPT | |
| SCHEMBL17845104 | 0.78 | ESR1 (0.42) | ESR1ESR2 | |
| SCHEMBL17845137 | 0.71 | USP7 (0.41) | DEGS1USP7ESR1ESR2PTGS2 | |
| SCHEMBL17845084 | 0.68 | GPBAR1 (0.44) | CNR1CNR2RAB9AALDH1A1MAPT | |
| SCHEMBL17845207 | 0.67 | GPBAR1 (0.49) | CNR1CNR2RAB9AALDH1A1MAPT | |
| SCHEMBL17845090 | 0.67 | L3MBTL1 (0.49) | RAB9AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2730191 | 0.65 | PTGS1 (0.43) | CNR1CNR2USP7ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406424-B | Estrogen receptor modulators and uses thereof | 豪夫迈·罗氏有限公司 | 2020-08-25 | — | — | CN | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9845291-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | DEGS1 3850/4885HSD17B1 69/4885HSD17B2 52/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | DEGS1 3850/4885HSD17B1 69/4885HSD17B2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.